Engineered immune cells take aim at stubborn childhood cancers
NCT ID NCT02992210
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new treatment using a patient's own immune cells, modified to recognize and attack a protein called GD2 found on many solid tumors. The trial includes 100 people aged 1 to 65 with tumors that have not responded to standard therapy. The goal is to see if these modified cells are safe and can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 4SCAR-GD2 CAR T cells (genetically modified immune cells targeting GD2)
- What this could lead to
- If successful, this could offer a new treatment option for patients with hard-to-treat solid tumors that express GD2.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with only 100 participants, so results may not apply broadly. Side effects from the modified cells are possible and are being closely monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?
- Can a Dual-Pronged antibody outsmart advanced cancers?